chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Hot sweaty, rapid heart rate with arrhythmia.  Very low blood sugar (I am not diabetic).  Blood sugar of 27.  Ambulance came and had to give adenosine.  Resolved to tachycardia.  Given multiple doses of glucose to recover blood sugar.  I do not know if vaccine caused this or not, but thought it would be best to report incase others have had a similar experience.  I am following up with a cardiologist and my primary doctor today.
A report has been received from a Health Professional concerning an 8 year old, female subject, who had been receiving FLUMIST. FLUMIST started on 07-Nov-2013. It was reported that a patient inadvertently received FLUMIST two days in a row, one at the doctor office and the other at school/administration of extra dose which started on 07-Nov-2013. The outcome of the event of administration of extra dose is unknown. The report was considered to be non-serious.
tongue felt numb on third day after receiving second shot for about 3 days then woke up 4/5/21 with no movement to left side of face. went to urgent care and was diagnosed with bells palsy .
We received the following literature report on 15 JUN 2009:  15 children between 6 and 59 months of age were vaccinated for the first time with an influenza vaccine (batch no. and manufacturer unknown) at the start of each influenza season (defined from 01 NOV to 30 APR) from 1999-2000 through 2006/2007.  The children received a total of two doses (fully vaccinated).  Vaccine effectiveness among fully vaccinated children as compared with unvaccinated children was 86% (95% confidence interval: 29-97%) for medically attended, laboratory-confirmed influenza illness.  Vaccine effectiveness for the partially vaccinated group was 73% (95% confidence interval: 3-93%) as compared with the unvaccinated group.  This case refers to one child (for other children, please refer to reference cases MA2009-1708 to MA2009-1710 and MA2009-1712 to MA2009-1722).  Laboratory-confirmed influenza illness was reported (date?). Request was sent on 22 JUN 2009, no follow-up information received.
Patient presented to pharmacy on 8/19/18 with redness across her entire upper arm that she stated felt hot and had been spreading over the last two days. She said that the day prior, 8/18/18, she had experienced a great deal of swelling and her elbow was "messed up", but that had resolved. She reported that she is unable to take antihistamines, so I advised her to monitor the rash and seek medical attention if it worsens. I suggested trying to get in touch with her physician to determine if she should take a course of steroids.
Immediately after the second vaccine within a few hours my right arm was numb and tingly. It has continued to progress all over the right side of my body including my face, neck, leg and foot. I have seen my Primary care physician, urgent care, and ER. I was recently referred to a neurologist and had a brain MRI. I have been put on prednisone so we will see if that helps. My neurologist believes I have transverse Myelitis from the vaccine. It has been consistent for 6 months.
shot was painful; This case was reported by a consumer via interactive digital media and described the occurrence of pain in an unspecified number of patients who received Herpes zoster (Shingles vaccine) for prophylaxis.   Previously administered products included Shingles shot (took last year 1 other shingles shot).   On an unknown date, the patient received the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced pain. On an unknown date, the outcome of the pain was unknown.   It was unknown if the reporter considered the pain to be related to Shingles vaccine.     Additional Information: GSK Receipt Date: 04-Oct-2022 Reporter's Comment: This case was reported via interactive digital media. The reporter stated that got the first shot which was painful for their old folks but going for number 2 in about a week, sure don't want this shingles heard bad things; now they did take just last year 1 other shingles shot, but was told was not strong enough, take these new ones x2. Additional Supportive Information: This case had been linked with US2022AMR142459, reported by same reporter. The follow up would not possible, as no contact, details were available.; Sender's Comments:  US-GSK-US2022AMR142459:reporter´s case
He was feeling depressed; Productive cough; having chills off; Nasal congestion; This spontaneous case was reported by a consumer and describes the occurrence of NASAL CONGESTION (Nasal congestion), DEPRESSION (He was feeling depressed), PRODUCTIVE COUGH (Productive cough) and CHILLS (having chills off) in a 64-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product UPADACITINIB (RINVOQ) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis (MODERATE TO SEVERE ).   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and UPADACITINIB (RINVOQ) (Oral) at an unspecified dose. In November 2021, the patient experienced NASAL CONGESTION (Nasal congestion), PRODUCTIVE COUGH (Productive cough) and CHILLS (having chills off). On an unknown date, the patient experienced DEPRESSION (He was feeling depressed). At the time of the report, NASAL CONGESTION (Nasal congestion) was resolving, DEPRESSION (He was feeling depressed) had not resolved and PRODUCTIVE COUGH (Productive cough) and CHILLS (having chills off) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  No concomitant and treatment medications were provided.  It was reported that patient was having chills off and on but never checked to see if he had a fever. He was feeling depressed but denied any thought of harming or suicide himself.  The reporter's causality for the evens of nasal congestion, depression, chills and productive cough with Rinvoq(upadacitinib) was no reasonable possibility. . This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in
pt came in a couple days after received his flu shot with a complained of a red opened sore about 1cm closer to the left arm pit. He said that it was from the flu vaccine, but the flu vaccine was given at the deltoid area. Pt said it's a little pain, but not big enough to go see the doctor.  Offer pt a $10 gift card so he can buy any medication needed OTC. Also log in an adverse reaction so pt has it on record. Gave him our contacts and his claim number.
vagina returned to post-menopausal moisture level and hot flashes stopped; nipples/breasts became extremely tender/sore; This is a spontaneous report from a contactable Other HCP (patient). A 57-year-old not pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: E112884/6022728) intramuscular at left arm on 04Jan2021 10:15 AM for COVID-19 immunization. Medical history included mild COPD (Chronic obstructive pulmonary disease) and diagnosis of DCIS (Ductal carcinoma in situ), had breast implants. No covid prior vaccination. No other vaccine in four weeks. No other medications in two weeks. Patient was 57 years old and am 6+ years post-menopausal. The day after vaccine, on 05Jan2021 08:00 AM, her nipples/breasts became extremely tender/sore, her vagina returned to post-menopausal moisture level and hot flashes stopped. Patient was 11 days out from vaccine and the symptoms have not stopped. She has not experienced these symptoms at any time after going through menopause. Events resulted in emergency room visit. No treatment received. The outcome of "nipples/breasts became extremely tender/sore" was not recovered. Covid test via Nasal Swab on 04Jan2021, 07Jan2021, 11Jan2021 was Negative, result of Nasal Swab covid test on 14Jan2021 was unknown.
The initial case was missing the following minimum criteria: identifiable patient. Upon receipt of follow-up information on 06Sep2017, this case now contains all required information to be considered valid. This is a spontaneous report from a contactable other HCP via Pfizer sales representative. A 16-year-old male patient of an unspecified race received TRUMENBA (lot S26985, exp. date 31Jan2019) at single dose on 14Aug2017 via an unspecified route of administration. Relevant medical history and concomitant medication were not specified. On 14Aug2017 the patient experienced swelling and cellulitis at injection site. The outcome of the event cellulitis at injection site was reported as recovered while the outcome of the other adverse event was unknown.
vax given & 10 min post vax pt passed out hitting back of head;5min p/falling vomited x 3 partially undigested food;color pale & sweating, BP 60/32, HR 46;transported to hosp by EMS
2 days after shot developed numbness and tingling in left wrist and hand, this did not resolve.  Client saw her provider and was given Prednisone.  Symptoms have since resolved
Notice a few spots (3-4) around body on chest area. On 02/3/05 noticed more spots (faint) lower in body. 2/4/05 more spots appeared and called nurse to inquiry whether could be pox, she recommended to watch it.  2/2 and 2/3 also had low grade fever and given Infant Tylenol and fever decreased. On 2/5 red was face and had welt on side of face, disappeared after 1 hour, was lethargic. 2/6 was also lethargic, mom nursed baby for 1 hour and noticed that had welts and red rash. Mom discovered the rash/welts were all over body, there were 2-3 spots together like clusters and some individual. At about 10AM baby was not lethargic, called doctor who recommended Benadryl and it really helped and at least redness was gone and started to clear up. Reaction different to allergy to amoxicillin. 2/8 only a few spots remain.
When pt. ate breakfast this morning, he said everything tasted bitter, like it does when he has the flu.
- severe body ache, low grade temperature, uncontrollable shaking from chills, severe fatigue set in approx. 19 hours post vaccination - symptoms disappeared by 12pm 4/1
Systemic: Chest Tightness / Heaviness / Pain-Medium, Systemic: Dizziness / Lightheadness-Medium, Systemic: Exhaustion / Lethargy-Medium, Additional Details: Patient complains of chest tightness and requests to vitals checked, nurse and lpn from minute clinic checks her and read: 144/80 bp, oxygen levels 100, and heart rate 74. nurse comes back to recheck her in 5 minutes and believes she may just feel nervous due to the second shot, patient suggests she go outside for fresh air, and end up going home, we call to check up on her, and symptoms are the same, will let us know how she feels and will call dr if symptoms dont go away
feverish; chills and aches upon waking at 7am, got progressively worse.; chills and aches upon waking at 7am, got progressively worse.; Dose Number:3; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from a sales representative. The reporter is the patient.  A 45 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 28Nov2021 13:00 (Lot number: FJ1620) at the age of 45 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "depression" (unspecified if ongoing); "Anxiety" (unspecified if ongoing); "Known allergies: Lactose intolerant" (unspecified if ongoing); "Known allergies:Gluten sensitivity" (unspecified if ongoing). Concomitant medication(s) included: FLUOXETINE. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: EN6206, Location of injection: Arm Left), administration date: 07Mar2021, when the patient was 45 years old, for COVID-19 Immunization, reaction(s): "no ADRs"; Bnt162b2 (Dose Number: 2, Batch/Lot No: EN6204, Location of injection: Arm Left), administration date: 28Mar2021, when the patient was 45 years old, for COVID-19 Immunization, reaction(s): "no ADRs". The following information was reported: IMMUNISATION (non-serious) with onset 28Nov2021 13:00, outcome "unknown", described as "Dose Number:3"; PYREXIA (non-serious) with onset 29Nov2021 07:00, outcome "recovering", described as "feverish"; PAIN (non-serious), CHILLS (non-serious) all with onset 29Nov2021 07:00, outcome "not recovered" and all described as "chills and aches upon waking at 7am, got progressively worse.". Therapeutic measures were not taken as a result of pyrexia, pain, chills.  Additional information:Adverse event, product problem or Error: Adverse events checked. Describe event, problem or product use error: No lab test performed. Suspect product name: BNT162B2, Manufacturer: Pfizer. Date of use: From 28Nov2021 13:00 to 28Nov2021 13:00.  No follow-up attempts are possible. No further information is expected.
Received Expired Dose; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received Expired Dose) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received Expired Dose). On 10-Dec-2021, EXPIRED PRODUCT ADMINISTERED (Received Expired Dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported.
continuous crying for 3-4 hr, inconsolable 103.6 R temp x 3 days w/the use of APAP & then liquid Motrin;
fever, headaches, joint pains, muscle pains, fatigue, swollen glands.
Fever; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 28-May-2021 and was forwarded to Moderna on 28-May-2021.    Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PYREXIA (Fever). At the time of the report, PYREXIA (Fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Dull ache / pain on inner left pectoral muscle for 3-4 weeks after each injection. Approximately 1-2 times per day, during the same timeframe as sore pectoral muscle, noticeable heart "flutter". This flutter was felt almost like heart skipping a beat / irregular heartbeat / heart palpitations for 5-15 seconds, but would resolve.
Initial information received on 04 February 2014 from a consumer who is the patient's parent. A 19-month-old male patient received a fourth dose of DTaP (manufacturer, route, site of administration not reported) on 12-MAY-2010. The patient's concomitant medications were not reported. The patient had received 3 previous doses of DTaP, manufacturer unknown, in the past. Within a few minutes the patient started coughing, had tingling of tongue, lips and started swelling of throat. The patient was treated with an EPIPEN and steroids, date not reported. The patient was transferred to the hospital emergency room. The symptoms resolved and the patient was able to go home. The patient had no further symptoms. The patient outcome was recovered. Documents held by sender: None.
Different degrees of headaches, dizziness, chronic pain on arm/legs (mainly knees, wrists, ankles), excessive fatigue, lack of appetite, gastrointestinal discomfort, abdominal pain, nausea, etc. These symptoms were characterized by a fast onset short duration and spontaneous recovery after 2 years.
little sore arm; a little itching; little tired; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (little sore arm), PRURITUS (a little itching) and FATIGUE (little tired) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001B21A) for an unknown indication.     No medical history was provided by the reporter.  Concomitant products included ESTROGENS CONJUGATED, MEDROXYPROGESTERONE ACETATE (PREMPRO) for an unknown indication.   On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (little sore arm), PRURITUS (a little itching) and FATIGUE (little tired). At the time of the report, PAIN IN EXTREMITY (little sore arm), PRURITUS (a little itching) and FATIGUE (little tired) outcome was unknown.      mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.   No treatment information were given.   This case was linked to MOD-2021-402890, MOD-2021-402893 (Patient Link).
dizzy; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (dizzy) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038A21A) for COVID-19 vaccination.     The patient's past medical history included Surgery.    On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Mar-2021, the patient experienced DIZZINESS (dizzy). On 19-Mar-2021, DIZZINESS (dizzy) had resolved. Not Provided      mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       She is scheduled for her second dose of vaccine no treatment medication was reported. no concomitant medication was reported.
14 patients administered bivalent Moderna covid-19 vaccines after 30-day beyond use date; No adverse event; 14 patients administered bivalent Moderna covid-19 vaccines after 30-day beyond use date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (14 patients administered bivalent Moderna covid-19 vaccines after 30-day beyond use date), PRODUCT STORAGE ERROR (14 patients administered bivalent Moderna covid-19 vaccines after 30-day beyond use date) and NO ADVERSE EVENT (No adverse event) in a 21-year-old patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 021H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 10-Jan-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) .5 milliliter. On 10-Jan-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (14 patients administered bivalent Moderna covid-19 vaccines after 30-day beyond use date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (14 patients administered bivalent Moderna covid-19 vaccines after 30-day beyond use date) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (14 patients administered bivalent Moderna covid-19 vaccines after 30-day beyond use date), PRODUCT STORAGE ERROR (14 patients administered bivalent Moderna covid-19 vaccines after 30-day beyond use date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        The action taken with mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) was unknown.   For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (14 patients administered bivalent Moderna covid-19 vaccines after 30-day beyond use date) and PRODUCT STORAGE ERROR (14 patients administered bivalent Moderna covid-19 vaccines after 30-day beyond use date).    Concomitant product use was not provider by the reporter.  No patients have been administered monovalent vaccine after the beyond use date. Doses were administered from 08-Dec-2022 to 10-Jan-2023. Date the vial was initially stored in the refrigerator was 24-Oct-2022. The vials did not undergo temperature excursions.   Treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-703586 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 23-Jan-2023: Follow-up received include patient demographics and narrative updated. On 24-Jan-2023: Follow-up received include no new information.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-703586:Master case - 1st adult
The patient received the second vaccine 7 days early because his first vaccine dose was administered on 3/22/2021.
MISSED PERIODS; This spontaneous report received from a patient via a company representative concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received ustekinumab (solution for infusion, intravenous, batch number was not reported) dose, frequency, and therapy dates were not reported for an unspecified indication. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose, start therapy date were not reported for prophylactic vaccination. Batch number was not reported. The company is unable to perform follow up to request batch/lot numbers. No concomitant medications were reported. On 01-MAY-2021, the subject experienced missed periods. Laboratory data (dates unspecified) included: Pregnancy test (NR: not provided) Negative. The action taken with covid-19 vaccine ad26.cov2.s was not applicable; and action taken with ustekinumab was not reported. The outcome of missed periods was not reported. This report was non-serious. This case, from the same reporter is linked to 20210510755.
A nurse reported that a 16 year old female received an injection of Tetanus Diphtheria Toxoids Adsorbed, Purogenated on 06/28/00. On 07/01/00, he developed an injection site reaction characterized by redness, swelling, and pain. She was treated with Ibuprofen, diphenhydramine, an antibiotic, and application of ice. As of 07/13/00, the patient had improved.
Cut where the needle went in; Got very ill; I still have a large warm red mark on my arm; I still have a large warm red mark on my arm; This case was reported by a consumer via interactive digital media and described the occurrence of injection site laceration in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced injection site laceration, illness, skin warm and erythema. On an unknown date, the outcome of the injection site laceration, skin warm and erythema were not recovered/not resolved and the outcome of the illness was unknown.   It was unknown if the reporter considered the injection site laceration, illness, skin warm and erythema to be related to Shingles vaccine.     Additional Information: GSK Receipt Date: 28-JAN-2023 Reporter's comments: This case was reported by the patient via interactive digital media. The reporter stated that the patient he/she had received the shingles vaccine and had got very ill. He/She still had a large warm red mark on his/her arm and cut where the needle went in at the time of reporting. Additional supportive information: As this was an RA case, the injection site laceration was captured conservatively. Follow-up would not possible as no contact details were available.
Arm started swelling and hurt-still swollen and hurts but wearing a sleeve that helps hasn't done any other treatment.